- Global Pharma News & Resources

New shape for Stalpex dry powder inhaler (DPI)

New shape for Stalpex dry powder inhaler (DPI)

Watford, England, May 24, 2021: Glenmark Pharmaceuticals is changing the design of its Stalpex (salmeterol xinafoate/fluticasone propionate) inhaler. The external shape of the dry powder inhaler will change but the internal mechanism will stay the same, so there will be no difference in the bioavailability of the active ingredients.


The new design is called G7 and compared to the G5 inhaler, it has a more prominent lever. The colour of the inhaler remains the same but the external shape is slightly different. 


“The new Stalpex inhaler is still bioequivalent to the originator product, and the new G7 design is unique to the Stalpex DPI,” said Martin Imms, General Manager of Glenmark Pharmaceuticals UK.


The new Stalpex inhaler is expected to be distributed to wholesalers from May 2021 and phased into the supply chain as older inhalers are replaced. Both old and new devices will be in circulation at the same time, until old stock has been used up.


“We would ask pharmacy dispensers to reassure patients that their new look Stalpex works in exactly the same way as the previous design, despite looking slightly different,” said Imms.


Stalpex dry powder inhaler delivers a combination of long-acting bronchodilator (salmeterol xinafoate 50mcg) and inhaled corticosteroid (fluticasone propionate 500mcg). It is indicated in the regular treatment of patients with severe asthma where use of a long-acting b2 agonist and inhaled corticosteroid is appropriate, and for the treatment of patients with COPD with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations who have significant symptoms despite regular bronchodilator therapy.


For further information or to order patient support materials please visit

Editor Details

Last Updated: 26-May-2021